Drug Profile
RES 700
Alternative Names: RES-700Latest Information Update: 28 Feb 2019
Price :
$50
*
At a glance
- Originator PharmaMax
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Allergic rhinitis
Most Recent Events
- 28 Feb 2019 No recent reports of development identified for clinical-Phase-Unknown development in Allergic-rhinitis in China